Vaccines for neurologic disorders
Apr. 03, 2021
At vero eos et accusamus et iusto odio dignissimos ducimus qui blanditiis praesentium voluptatum deleniti atque corrupti quos dolores et quas.
On Thursday, April 7, the Centers for Medicare and Medicaid (CMS) formalized its plan to cover the anti-amyloid drug aducanumab (Aduhelm®) only for patients enrolled in clinical trials. However, in response to concerns raised by the Alzheimer disease community, CMS will not have to approve these trials. Medicare will cover patients enrolled in any FDA- or NIH-approved trial. This is an important change that will allow more patients to access the drug in additional settings.
The Alzheimer’s Drug Discovery Foundation (ADDF) supports the need to gather more evidence about the clinical effectiveness of aducanumab, a question that was left unanswered in its clinical trials. While the CMS final policy is less restrictive, and an improvement over its earlier proposal, the ADDF would have preferred that CMS include patient registries as an alternative to clinical trials.
“Patient registries collect real-world evidence that more closely reflects the actual population living with Alzheimer disease, compared to the limited populations that enroll in clinical trials,” explained Dr. Howard Fillit, Co-Founder and Chief Science Officer at ADDF. “This approach would also have extended coverage of aducanumab to more patients currently living with Alzheimer’s disease.”
In another positive change, CMS will not automatically impose the same coverage restrictions for similar drugs coming down the pipeline if they present data showing they can improve clinical outcomes and receive traditional FDA approval instead of the accelerated approval granted to aducanumab. The ADDF strongly supports this change. “If you’ve seen one anti-amyloid antibody, then you’ve seen one anti-amyloid antibody," said Dr. Fillit. “Drugs in the same class are not necessarily equal and each should be evaluated and made available to patients on its own merits.”
How FDA and CMS evaluate, cover, and make Alzheimer disease drugs available is more important than ever. We are in a new era of Alzheimer disease drug development with many promising new drugs on the horizon that go beyond the traditional targets of amyloid and tau and work against the many underlying causes of Alzheimer disease.
Anti-amyloid treatments are just one piece of a complex Alzheimer disease puzzle
Alzheimer disease drugs currently being studied are driven by the biology of aging approach, which is based on the many biological processes that go awry in the aging brain. Aducanumab, and the anti-amyloid approach, is just one piece of this complex puzzle. More than three in four drugs in clinical trials today address non-amyloid targets, like inflammation, vascular dysfunction, and genetic alterations that contribute to the development of Alzheimer disease as we age.
“It is vital that we deliver on our promise to develop new therapies that target all of the underlying factors,” said Dr. Fillit. “Only by adopting a personalized approach that combines multiple therapies against a variety of targets tailored to each patient’s individual needs will we be able to effectively conquer Alzheimer’s.”
An essential part of bringing these drugs to market is validation of target-specific biomarkers, which is the sole focus of the ADDF’s Diagnostics Accelerator. Biomarker PET scans, blood tests, and even eye scans are being developed to measure how well the body responds to drug treatments in clinical trials. These same tests will eventually be available in doctors’ offices for rapid, noninvasive diagnosis of Alzheimer disease.
Although anything short of full coverage may be disappointing for some patients and families, there is more reason for optimism today than ever before. We are in a modern age of Alzheimer disease research that will deliver not just anti-amyloid drugs, but drugs that work against the many other factors that contribute to Alzheimer disease.
Source: News Release
Alzheimer's Drug Discovery Foundation
April 8, 2022